Dongsung Pharmaceutical

At a glance

Dongsung Pharmaceutical filed 106 disclosures in the last 12 months, including 6 insider, 3 5% holder and 3 issuance. The most recent key filing was on Apr 15.

Revenue for 2025 was ₩87.2B, down 1.4% on 2024. It made an operating loss of ₩10.1B. Debt was 621% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩41.2B and operating loss of ₩1.7B.

The 2025 annual report lists 307 employees with an average tenure of 6.7 years and average pay of ₩42.6M, #2025 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩110M each on average. It paid no cash dividend for 2025. (주)브랜드리팩터링 and related parties held 11.89% at year end.

Of 3 recent 5%+ holder reports, 2 raised and 1 cut a stake; the largest stake reported was 81.98% on Apr 15.

From the 2025 annual report

Staff: 307 (174 men, 133 women), of whom 36 on fixed-term contracts. Total pay for the year: ₩13.1B. Directors and auditors: 5, paid ₩549.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)브랜드리팩터링 holds 11.89%; with 0 related parties the group holds 11.89% of common shares at year end.

Auditor: 한울회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports